Gpr17 modulators,method of screening and uses thereof
AssigneesUniversita' Degli Studi Di Milano, Universita Degli Studi Di Pisa, Consiglio Nazionale Delle Ricerche
InventorsMaria Pia Abbracchio, Paolo Ciana, Gianenrico Rovati, Claudia Martini, Maria Letizia Trincavelli, Claudia Verderio
Life of this patent
Estimating the term…
Abstract
The invention provides GPR17 modulators, methods of screening and use thereof for diagnosis and therapy of diseases or dysfunctions involving GPR17 activation, particularly ischemic brain damage.
Claims18
1-17. (canceled)
A method for the identification of a GPR17 modulator, which essentially comprises the steps of:
- a) contacting GPR17 with a candidate compound, the latter being a nucleotide derivative or analog unable to interact with cysteinyl leukotriene receptors;
- b) determining the receptor response.
An antisense oligonucleotide selected from SEQ ID NO:
- 1 and SED ID NO:
- 2, or a functional analog thereof.
A method for the treatment of disorders involving GPR17 activation, comprising administering an effective amount of a GPR17 antagonist that interacts with the receptor nucleotide binding site.
A method leukotriene receptor-binding site, for the preparation of a therapeutic agent for the treatment of disorders involving GPR17 activation.
A diagnostic device comprising GPR17 nucleotide binding site.
A neuroprotective, anti-inflammatory and anti-ischemic agent, comprising a GPR17 antagonist.
A method for the treatment of cerebral, cardiac and renal ischemia, comprising administering an effective amount of a GPR17 antagonist.
A method for the treatment of ischemic brain damage, comprising administering an effective amount of an antisense oligonucleotide selected from SEQ ID NO:
- 1 and SEQ ID NO:
- 2
A method for the treatment of ischemic brain, heart and renal damage, comprising administering an effective amount of small interference RNAs directed against SEQ ID NO:
- 1 and SEQ ID NO:
- 2
Dependencies are inferred from the claim text.